Cryoglobulinaemic Glomerulonephritis, Hepatitis C
Conditions
Brief summary
CryoKid is a no-profit, multi-center, single-arm, open-label, pilot study. The study aims to evaluate the tolerability of MK-8742 (Elbasvir) / MK-5172 (Grazoprevir) administrated for 12 weeks without Ribavirin in patients with HCV chronic hepatitis (G1b and G4) and cryoglobulinemic nephropathy.
Interventions
Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
Sponsors
University of Florence
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Informed consent form signed, 2. Male or female at least 18 years of age at time of Screening. 3. Chronic infection with Hepatitis C virus G1b 4. Chronic infection with Hepatitis C virus G4 naïve, and experienced with baseline HCV RNA level \<800,000 IU/ml 5. Metavir score ranging between F0-F4 (with Child-Pugh score ranging from A5 to A6) 6. Diagnosis of mixed cryoglobulinemia MC (type III or II) according to standard criteria 7. Chronic renal impairment due to cryoglobulinemic nephropathy. Subjects with renal impairment will include CKD Stage 5 (eGFR \< 15mL/min or dialysis dependent), CKD Stage 4 (eGFR 15-29 mL/min), CKD Stage 3 eGFR (30-59 mL/min) and CKD Stage 2 (60-89 mL/min) HCV patients. 8. Albumin level ≥ 3.0 g/dl, 9. Platelet count ≥ 75 x 103/μL.
Exclusion criteria
1. Age \<18 years 2. Chronic infection with Hepatitis C virus G4 experienced with baseline HCV RNA level \>800,000 IU/ml 3. Patients with HCV genotype 1a, 2, 3, 5, 6, 4. Coexistence of life-threatening condition(s) unrelated to MC 5. Diagnosis of malignancy 6. Pregnancy or breast feeding. 7. Child-Pugh score \> A6 8. Decompensated cirrhosis or previous decompensation 9. Platelet count \< 75 x 103/μL 10. Albumin level \< 3 g/l 11. Co-infection with more than one HCV genotype. 12. Any serious or active medical illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance 13. HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive) 14. Known hypersensitivity to Grazoprevir, Elbasvir or any of its components
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SVR12 | march 2018-october 2018 | Percentage of participants achieving sustained virologic response 12 weeks after completing treatment (SVR12) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SVR24 | march 2018-december 2018 | Percentage of participants achieving Sustained Virologic Response 24 weeks after ending study treatment (SVR 24) |
| Clinical response: improvement or disappearance of MC clinical and biochemical stigmata | march 2018-december 2018 | Clinical response: improvement or disappearance of MC clinical and biochemical stigmata at the EOT, at week 12 and week 24 of follow-up. Improvement of the renal function at week 4, week 8, EOT at week 12 and week 24 of follow-up. |
| Tolerability: Number of participants experiencing an adverse event (AE) | march 2018-may 2018 | Tolerability: Number of participants experiencing an adverse event (AE) |
Contacts
Primary ContactANNA LINDA ZIGNEGO, MD, PhD
Backup ContactMONICA MONTI, PhD
Outcome results
None listed